Spinal Muscular Atrophy Clinical Trial
Official title:
A Pilot Study of the Natural History of Infants With Spinal Muscular Atrophy (SMA) Type 1
Background:
- Spinal muscular atrophy type 1 (SMA 1) causes severe muscle weakness and problems with
eating and breathing. The symptoms begin in infancy, and children affected with SMA 1 often
die in early childhood. Researchers want to collect information on how SMA symptoms progress
in first two years.
Objectives:
- To study how the symptoms of SMA 1 progress in infants and children.
Eligibility:
- Infants and children with SMA 1 born on or after January 1, 2007.
Design:
- Researchers will review the child s medical records and talk with parents by telephone.
- For children who are under 2 years of age, the researchers will review the child s
medical records and speak with you on telephone every 2-4 months. Phone calls with
parents will take about 10 minutes and will involve questions about symptoms of SMA 1.
Children will be followed until age 2.- Researchers are also interested in looking at
medical records of children who are no longer alive or who are more than 2 years of age.
Parents or children do not have to come to the NIH. They will provide consent to view these
records, and information over the telephone.
- No treatment or care will be provided as part of this study.
Objective:
To conduct a pilot, observational, retrospective and prospective, natural history study of
infants affected with spinal muscular atrophy type 1 (SMA 1). The goal is to assess the
feasibility of the study design in order to plan a larger study aimed at understanding the
changing natural history and obtain current data on survival of patients affected with SMA 1.
This information is important for designing clinical trials.
Study Population:
Up to 50 children born on or after January 1, 2007 with a clinical diagnosis of SMA 1 and
genetic testing consistent with a homozygous mutation of the SMN 1 gene on chromosome 5q13
will be enrolled in the study.
Design:
This is a longitudinal pilot study to demonstrate study design feasibility and test outcome
measures to assess the natural history of infants affected with SMA 1. Pertinent clinical and
demographic data will be collected. The data collection will be retrospective for deceased
infants and children who are alive but over age of 2 years at the time of enrollment. A
combination of retrospective and prospective data will be collected for infants who are alive
and less than 2 years of age at the time of enrollment. The data will be collected remotely
from the National Institutes of Health (NIH) by medical chart reviews and/or telephone
questionnaire obtained from the parent of the infant with SMA 1. Infants alive at enrollment
will be followed prospectively until age 2 years or death, whichever occurs first.
Outcome Measures:
The primary outcome of this pilot study is to demonstrate the feasibility of the study design
and outcome measures in patients with SMA 1.
Secondary outcomes include evaluation for time of events, i.e., time of ventilator support
for >=16 hours a day continuously for more than 2 weeks and time of death.
Additional demographic and clinical data pertinent to respiratory and nutritional aspects
will be collected to assess possible factors influencing the outcome measures.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04851873 -
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)
|
Phase 3 | |
Completed |
NCT03223051 -
Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT04335942 -
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor
|
N/A | |
Recruiting |
NCT05794139 -
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
|
Phase 2 | |
Not yet recruiting |
NCT06300996 -
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
|
N/A | |
Completed |
NCT02003937 -
Aerobic Training in Patients With Spinal Muscular Atrophy Type III
|
N/A | |
Not yet recruiting |
NCT00961103 -
Motor Development and Orthoses in Spinal Muscular Atrophy (SMA)
|
N/A | |
Completed |
NCT00227266 -
Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy
|
Phase 2 | |
Completed |
NCT00374075 -
Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy
|
Phase 1 | |
Enrolling by invitation |
NCT05539456 -
Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
|
||
Recruiting |
NCT05779956 -
Personalized Medicine for SMA: a Translational Project
|
||
Recruiting |
NCT03300869 -
Natural History of Types 2 and 3 SMA in Taiwan
|
||
Recruiting |
NCT03217578 -
Neonatal Spinal Muscular Atrophy (SMA) Screening
|
||
Completed |
NCT01703988 -
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02235090 -
Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting
|
N/A | |
Completed |
NCT02123186 -
Newborn Screening for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00756821 -
A Pilot Study of Biomarkers for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00004771 -
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
|
Phase 2 | |
Recruiting |
NCT05366465 -
Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France
|
||
Recruiting |
NCT06310421 -
Spinal Muscular Atrophy Neonatal Screening Program
|